A Phase 2 interventional study of Bempedoic acid 180mg and Ezetimibe 10mg in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 11th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 11th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 2, and was the 11th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
Drug: Bempedoic acid 180mg · Drug: Ezetimibe 10mg · Drug: Atorvastatin 20mg
Matching placebos taken orally, daily.
Other: Placebo
bempedoic acid 180 mg
Also known as: ETC-1002
ezetimibe 10 mg
Also known as: Zetia
atorvastatin 20 mg
Also known as: Lipitor
placebo
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Percent change from Baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing LDL-C values were imputed using last observation carried forward (LOCF), with only post-Baseline values carried forward. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
Time frame: Baseline; Week 6
Percent Change From Baseline in Lipid Profile Parameters at Week 6
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Baseline apolipoprotein B (apoB) was measured only at predose/Day 1. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing values were imputed using LOCF, with only post-Baseline values carried forward. non-HDL-C, non-high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
Time frame: Baseline; Week 6
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6
Percent change is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the predose Day 1/Week 0 (Treatment Visit 1) value. If only one value is available either at Week -1 (Screening Visit 2) or Week 0 (Treatment Visit 1), then that value is used as Baseline. Missing values were imputed using LOCF, with only post-Baseline values carried forward.
Time frame: Baseline; Week 6
Number of Participants With LDL-C <70 mg/dL at Week 6
Analysis was based on LOCF values. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
Time frame: Week 6
Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6
If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
Time frame: Baseline; Week 6
| Milestone | Placebo | Triplet Therapy |
|---|---|---|
| Started | 20 | 43 |
| Completed | 19 | 43 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Percent change from Baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing LDL-C values were imputed using last observation carried forward (LOCF), with only post-Baseline values carried forward. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
| percent change | Placebo | Triplet Therapy |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6 | -3.1 ± 3.27 | -63.6 ± 1.67 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Baseline apolipoprotein B (apoB) was measured only at predose/Day 1. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing values were imputed using LOCF, with only post-Baseline values carried forward. non-HDL-C, non-high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
| percent change | Placebo | Triplet Therapy |
|---|---|---|
| non-HDL-C | -1.3 ± 2.56 | -60.0 ± 1.60 |
| TC | -1.1 ± 2.24 | -47.1 ± 1.63 |
| apoB | 0.6 ± 2.24 | -53.5 ± 1.57 |
| TG | 8.9 ± 5.95 | -27.4 ± 2.79 |
| HDL-C | 0.4 ± 2.26 | -1.1 ± 1.47 |
Percent change is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the predose Day 1/Week 0 (Treatment Visit 1) value. If only one value is available either at Week -1 (Screening Visit 2) or Week 0 (Treatment Visit 1), then that value is used as Baseline. Missing values were imputed using LOCF, with only post-Baseline values carried forward.
| percent change | Placebo | Triplet Therapy |
|---|---|---|
| Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6 | -2.7 (-19.8 to 17.9) | -47.7 (-66.0 to -22.7) |
Analysis was based on LOCF values. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
| Participants | Placebo | Triplet Therapy |
|---|---|---|
| Number of Participants With LDL-C <70 mg/dL at Week 6 | 0 | 37 |
If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.
| Participants | Placebo | Triplet Therapy |
|---|---|---|
| Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6 | 0 | 39 |
Collected over up to 6 weeks plus 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| Triplet Therapy | 0/43 (0%) | 0/43 (0%) | 15/43 (34.9%) |
| Event | Placebo | Triplet Therapy |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/20 | 1/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/20 | 1/43 |
| Back painMusculoskeletal and connective tissue disorders | 1/20 | 1/43 |
| Joint swellingMusculoskeletal and connective tissue disorders | 1/20 | 0/43 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/20 | 0/43 |
| HeadacheNervous system disorders | 1/20 | 2/43 |
| DizzinessNervous system disorders | 1/20 | 1/43 |
| FolliculitisInfections and infestations | 1/20 | 0/43 |
| NauseaGastrointestinal disorders | 1/20 | 1/43 |
| Ear painEar and labyrinth disorders | 1/20 | 0/43 |
| Age, Continuous(years) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| Mean | 61.2 ± 7.77 | 61.2 ± 12.26 | 61.2 ± 10.97 |
| Sex: Female, Male(Participants) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| Female | 14 | 26 | 40 |
| Male | 6 | 17 | 23 |
| Race/Ethnicity, Customized(Participants) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| American Indian or Alaska native | 0 | 1 | 1 |
| Asian | 1 | 1 | 2 |
| Black or African American | 3 | 7 | 10 |
| White | 16 | 34 | 50 |
| Baseline LDL-C, non-HDL-C, HDL-C, TC, and TG Values(milligrams per deciliter (mg/dL)) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| LDL-C | 155.90 ± 13.749 | 154.29 ± 17.913 | 154.80 ± 16.609 |
| non-HDL-C | 183.13 ± 18.363 | 183.59 ± 27.347 | 183.44 ± 24.698 |
| HDL-C | 52.03 ± 12.977 | 52.05 ± 12.936 | 52.04 ± 12.844 |
| TC | 235.13 ± 21.196 | 235.67 ± 26.992 | 235.50 ± 25.125 |
| TG | 139.53 ± 62.475 | 150.70 ± 81.375 | 147.15 ± 75.560 |
| Baseline Apolipoprotein B (apoB) Values(mg/dL) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| Mean | 119.2 ± 15.25 | 118.0 ± 19.89 | 118.4 ± 18.42 |
| Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values(milligrams per Liter) | Placebo | Triplet Therapy | Total |
|---|---|---|---|
| Median | 1.64 (0.12 to 9.51) | 1.94 (0.27 to 29.16) | 1.88 (0.12 to 29.16) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Jun 2017, 4 months.
Results were first posted in Apr 2020, 2 years 10 months after primary completion. A results delay was requested in Jul 2018.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 4 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid